Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
125.25
+3.75 (3.09%)
Aug 21, 2026, 10:34 AM EDT - Market open
Kymera Therapeutics Stock Forecast
Stock Price Forecast
According to 24 analysts polled by S&P Global, Kymera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $130.91. The average 1-year stock price forecast is 4.52% higher than the current stock price, while the lowest is $111 (-11.38%) and the highest is $155 (+23.75%).
Price Target: $130.91 (+4.52%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 18 | 17 | 17 | 17 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 23 | 24 | 23 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $140 | Buy | Maintains | $140 | +11.78% | Aug 20, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $132 | Buy | Maintains | $132 | +5.39% | Aug 13, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $120 → $121 | Buy | Maintains | $120 → $121 | -3.39% | Aug 7, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $125 → $123 | Buy | Reiterates | $125 → $123 | -1.80% | Aug 7, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $116 | Buy | Reiterates | $116 | -7.39% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
106.18M
from 39.21M
Increased by 170.80%
Revenue Next Year
45.20M
from 106.18M
Decreased by -57.43%
EPS This Year
-3.80
from -3.69
EPS Next Year
-4.96
from -3.80
EPS and Forward PE are based on non-GAAP adjusted numbers.